The epidemiological study of the craniocerebral trauma (CCT) indicates its signifi cant prevalence. That is why scientists from all over the world continue to study pathogenesis and improve diagnostic and therapeutic and rehabilitation measures for CCT. One of the directions of therapy is the impact on the processes of neuroplasticity. According to many researchers, the most eff ective method of such compensatory therapy is the use of inhibitors of acetylcholinesterase (in particular Neuromidin), which prevents the destruction of acetylcholine in the synaptic cleft. In our study, 40 patients with mild-to-moderate CCT were involved in the acute and early recovery period. For these patients the dug Neuromidin was included in the course of traditional therapy. The results of the study showed that the inclusion of the drug Neuromidin in the scheme of the CCT therapy gives a more pronounced therapeutic effect. The prescription of this drug favoured the more complete regression of neurological disorders in the acute period of CCT. This was confi rmed by a signifi cant improvement in the processes of neuroplasticity in the form of an increase in the concentration of beta-NGF in the serum. The obtained data allow us to recommend Neuromidin for inclusion in therapy schemes for patients with CCT.